AU2016319107B2 - Methods of treating neurodegenerative disorders in a particular patient population - Google Patents

Methods of treating neurodegenerative disorders in a particular patient population Download PDF

Info

Publication number
AU2016319107B2
AU2016319107B2 AU2016319107A AU2016319107A AU2016319107B2 AU 2016319107 B2 AU2016319107 B2 AU 2016319107B2 AU 2016319107 A AU2016319107 A AU 2016319107A AU 2016319107 A AU2016319107 A AU 2016319107A AU 2016319107 B2 AU2016319107 B2 AU 2016319107B2
Authority
AU
Australia
Prior art keywords
subject
apoe4
score
mmse
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016319107A
Other languages
English (en)
Other versions
AU2016319107A1 (en
Inventor
Susan ABUSHAKRA
John Hey
Petr Kocis
Aidan POWER
Martin TOLAR
Jeremy Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzheon Inc
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016319107(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of AU2016319107A1 publication Critical patent/AU2016319107A1/en
Application granted granted Critical
Publication of AU2016319107B2 publication Critical patent/AU2016319107B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016319107A 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population Active AU2016319107B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (2)

Publication Number Publication Date
AU2016319107A1 AU2016319107A1 (en) 2018-03-22
AU2016319107B2 true AU2016319107B2 (en) 2021-02-25

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016319107A Active AU2016319107B2 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102412997B1 (enExample)
CN (3) CN116712423A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4289820A3 (en) 2014-03-21 2024-03-13 Alzheon, Inc. Compounds for use in treating alzheimer's disease in apoe4+/+ patients
JP6789579B2 (ja) * 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
US12285400B2 (en) * 2018-08-01 2025-04-29 Alzheon, Inc. Sulfopropanoic acid derivatives for treating neurodegenerative disorders
DK3829563T3 (en) * 2018-08-01 2025-02-24 Alzheon Inc 3-sulfopropanoic acid for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CA3144008A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
JP2024542844A (ja) * 2021-12-09 2024-11-15 アルツェオン・インコーポレーテッド アルツハイマー病の処置に使用されるａｌｚ－８０１
US20250127734A1 (en) * 2022-02-07 2025-04-24 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220122A1 (en) * 2006-10-12 2014-08-07 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
FI951701L (fi) 1992-10-13 1995-04-10 Univ Duke Menetelmät Alzheimerin taudin tunnistamiseksi
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
CN1867795B (zh) 2003-08-11 2010-12-08 加州理工学院 微流体的大规模集成
WO2007069073A2 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
BRPI0719379A2 (pt) 2006-11-24 2014-02-11 Ac Immune Sa Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
AU2014262890B2 (en) 2013-05-06 2019-01-31 Takeda Pharmaceutical Company Limited Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
NZ723884A (en) * 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
EP4289820A3 (en) * 2014-03-21 2024-03-13 Alzheon, Inc. Compounds for use in treating alzheimer's disease in apoe4+/+ patients
JP6789579B2 (ja) * 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220122A1 (en) * 2006-10-12 2014-08-07 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CALTAGIRONE CARLO ET AL, AGING CLINICAL AND EXPERIMENTAL RESEARCH GERMANY, (2012-12-01), vol. 24, no. 6, doi:10.3275/8585, ISSN 1720-8319, pages 580 - 587 *
PAUL S. AISEN ET AL, ARCHIVES OF MEDICAL SCIENCE, (2011-01-01), vol. 1, doi:10.5114/aoms.2011.20612, ISSN 1734-1922, pages 102 - 111 *
SLEEGERS KRISTEL et al., "The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects", Trends in Genetics, 18 Jan 2010, vol. 26(2), pages 84 - 93 *

Also Published As

Publication number Publication date
JP2022145949A (ja) 2022-10-04
EP4275750A2 (en) 2023-11-15
HUE062511T2 (hu) 2023-11-28
WO2017044840A1 (en) 2017-03-16
EP3347002A1 (en) 2018-07-18
CA2997376A1 (en) 2017-03-16
JP2020200352A (ja) 2020-12-17
EP3347002B1 (en) 2023-06-07
MX2022003128A (es) 2022-08-02
US11191742B2 (en) 2021-12-07
CA2997376C (en) 2024-05-14
US20220096406A1 (en) 2022-03-31
MD3347002T2 (ro) 2023-10-31
PL3347002T3 (pl) 2023-11-13
SI3347002T1 (sl) 2023-12-29
KR102412997B1 (ko) 2022-06-23
KR20220042480A (ko) 2022-04-05
HK1257874A1 (en) 2019-11-01
DK3347002T3 (da) 2023-08-14
KR102547164B1 (ko) 2023-06-22
CN116712423A (zh) 2023-09-08
KR20180051561A (ko) 2018-05-16
MX2018003023A (es) 2018-06-06
EP4275750A3 (en) 2024-01-17
HRP20230809T1 (hr) 2023-10-27
CN116712422A (zh) 2023-09-08
US20230414541A1 (en) 2023-12-28
JP2018526407A (ja) 2018-09-13
RS64481B1 (sr) 2023-09-29
JP6789579B2 (ja) 2020-11-25
ES2952727T3 (es) 2023-11-03
JP2025065545A (ja) 2025-04-17
JP7128536B2 (ja) 2022-08-31
FI3347002T3 (fi) 2023-08-10
PT3347002T (pt) 2023-07-27
SMT202300250T1 (it) 2023-09-06
MX392677B (es) 2025-03-24
CN108289870A (zh) 2018-07-17
LT3347002T (lt) 2023-09-11
AU2016319107A1 (en) 2018-03-22
EP3347002A4 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
US20230414541A1 (en) Methods of treating neurodegenerative disorders in a particular population
ES2698927T3 (es) Terapia para trastornos neurológicos basada en baclofeno y acamprosato
CN109890391B (zh) 痴呆症的治疗
CN107669668A (zh) 治疗多发性硬化症的组合疗法
EP3962488A1 (en) A method of treating mental, behavioral, cognitive disorders
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
US12042493B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
HK40056250B (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
HK40056250A (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
AU2019211135A1 (en) Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
WO2018197383A1 (en) Idalopirdine-based combinatorial therapies of alzheimer's disease
HK40003690B (en) Treatment of dementia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)